Van ECK Associates Corp Has $5.62 Million Stock Holdings in Becton, Dickinson and Company $BDX

Van ECK Associates Corp increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 23.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 37,144 shares of the medical instruments supplier’s stock after purchasing an additional 6,973 shares during the period. Van ECK Associates Corp’s holdings in Becton, Dickinson and Company were worth $5,621,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Nissay Asset Management Corp Japan raised its holdings in Becton, Dickinson and Company by 4.7% in the 2nd quarter. Nissay Asset Management Corp Japan now owns 39,329 shares of the medical instruments supplier’s stock valued at $5,952,000 after acquiring an additional 1,782 shares during the period. Kingsview Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $5,551,000. Beacon Pointe Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $404,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $343,000. Finally, Glenview Trust Co acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $10,932,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Barclays boosted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Jefferies Financial Group restated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $187.67.

Becton, Dickinson and Company Stock Up 0.2%

NYSE BDX opened at $187.58 on Thursday. The business has a fifty day moving average price of $168.75 and a two-hundred day moving average price of $160.44. The stock has a market capitalization of $51.69 billion, a PE ratio of 56.50, a PEG ratio of 13.19 and a beta of 0.21. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the company posted $3.68 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.